Prx i suppresses K-ras-driven lung tumorigenesis by opposing redox-sensitive ERK/Cyclin D1 pathway

Antioxidants and Redox Signaling

Volumn 19, Issue 5, 2013, Pages 482-496

  Park, Young Ho ^a,b   Kim, Sun Uk ^a,b   Lee, Bo Kyoung ^a   Kim, Hyun Sun ^a   Song, In Sung ^c   Shin, Hye Jun ^a,d   Han, Ying Hao ^a   Chang, Kyu Tae ^a   Kim, Jin Man ^d   Lee, Dong Seok ^a,e   Kim, Yeul Hong ^f   Choi, Chang Min ^g   Kim, Bo Yeon ^a   Yu, Dae Yeul ^a,b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Inje University   (South Korea)

^d Chungnam National University   (South Korea)

^e Kyungpook National University   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PEROXIREDOXIN 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR NRF2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CYCLIN D1; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; NF-E2-RELATED FACTOR 2; PEROXIREDOXINS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 84877597805     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4421     Document Type: Article

References (60)

1. Abbas K, Breton J, Planson AG, Bouton C, Bignon J, Seguin C, Riquier S, Toledano MB, and Drapier JC. Nitric oxide activates an Nrf2/sulfiredoxin antioxidant pathway in macrophages. Free Radic Biol Med 51: 107-114, 2011
2. Alexandrova AY, Kopnin PB, Vasiliev JM, and Kopnin BP. ROS up-regulation mediates Ras-induced changes of cell morphology and motility. Exp Cell Res 312: 2066-2073, 2006
3. Arber N, Sutter T, Miyake M, Kahn SM, Venkatraj VS, Sobrino A, Warburton D, Holt PR, and Weinstein IB. Increased expression of cyclin D1 and the Rb tumor suppressor gene in c-K-ras transformed rat enterocytes. Oncogene 12: 1903-1908, 1996
4. Avila PC, Kropotov AV, Krutilina R, Krasnodembskay A, Tomilin NV, and Serikov VB. Peroxiredoxin V contributes to antioxidant defense of lung epithelial cells. Lung 186: 103-114, 2008
5. Bae SH, Sung SH, Cho EJ, Lee SK, Lee HE, Woo HA, Yu DY, Kil IS, and Rhee SG. Concerted action of sulfiredoxin and peroxiredoxin I protects against alcohol-induced oxidative injury in mouse liver. Hepatology 53: 945-953, 2011
6. Butterfield LH, Merino A, Golub SH, and Shau H. From cytoprotection to tumor suppression: The multifactorial role of peroxiredoxins. Antioxid Redox Signal 1: 385-402, 1999
7. Cao J, Schulte J, Knight A, Leslie NR, Zagozdzon A, Bronson R, Manevich Y, Beeson C, and Neumann CA. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J 28: 1505-1517, 2009
8. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R, and McCubrey JA. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ ERK pathway (Review). Int J Oncol 22: 469-480, 2003
9. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH, and Yoo YJ. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 289: 507-512, 2001
10. Chen MF, Keng PC, Shau H, Wu CT, Hu YC, Liao SK, and Chen WC. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int J Radiat Oncol Biol Phys 64: 581-591, 2006
11. Choi MH, Lee IK, Kim GW, Kim BU, Han YH, Yu DY, Park HS, Kim KY, Lee JS, Choi C, Bae YS, Lee BI, Rhee SG, and Kang SW. Regulation of PDGF signalling and vascular remodelling by peroxiredoxin II. Nature 435: 347-353, 2005
12. Coleman ML, Marshall CJ, and Olson MF. Ras promotes p21(Waf1/Cip1) protein stability via a cyclin D1-imposed block in proteasome-mediated degradation. EMBO J 22: 2036-2046, 2003
13. Collins LG, Haines C, Perkel R, and Enck RE. Lung cancer: Diagnosis and management. Am Fam Physician 75: 56-63, 2007
14. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, and Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475: 106-109, 2011
15. Egler RA, Fernandes E, Rothermund K, Sereika S, de Souza-Pinto N, Jaruga P, Dizdaroglu M, and Prochownik EV. Regulation of reactive oxygen species, DNA damage, and c-Myc function by peroxiredoxin 1. Oncogene 24: 8038-8050, 2005
16. Fan J and Bertino Jr. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 14: 2595-2607, 1997
17. Fujii J and Ikeda Y. Advances in our understanding of peroxiredoxin, a multifunctional, mammalian redox protein. Redox Rep 7: 123-130, 2002
18. Graves JA, Metukuri M, Scott D, Rothermund K, and Prochownik EV. Regulation of reactive oxygen species homeostasis by peroxiredoxins and c-Myc. J Biol Chem 284: 6520-6529, 2009
19. Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, and Rosen N. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70: 6804-6814, 2010
20. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 16: 706-733, 2009
21. Hofmann B, Hecht HJ, and Flohe L. Peroxiredoxins. Biol Chem 383: 347-364, 2002
22. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K, and Yamamoto M. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 15: 3423-3432, 2009
23. Immenschuh S and Baumgart-Vogt E. Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777, 2005
24. Jemal A, Siegel R, Xu J, and Ward E. Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010
25. Joshi G, Aluise CD, Cole MP, Sultana R, Pierce WM, Vore M, St Clair DK, and Butterfield DA. Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: Implications for oxidative stress-mediated chemobrain. Neuroscience 166: 796-807, 2010
26. Kerkhoff E and Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene 17: 1457-1462, 1998
27. Kim HJ, Chae HZ, Kim YJ, Kim YH, Hwangs TS, Park EM, and Park YM. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol Toxicol 19: 285-298, 2003
28. Kim JH, Bogner PN, Baek SH, Ramnath N, Liang P, Kim HR, Andrews C, and Park YM. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res 14: 2326-2333, 2008
29. Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, and Park YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: Implication to tumor biology. Cancer Res 67: 546-554, 2007
30. Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, and Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res 66: 7136-7142, 2006
31. Kim YS, Lee HL, Lee KB, Park JH, Chung WY, Lee KS, Sheen SS, Park KJ, and Hwang SC. Nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer. Korean J Intern Med 26: 304-313, 2011
32. Klein EA and Assoian RK. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 121: 3853-3857, 2008
33. Le Belle JE, Orozco NM, Paucar AA, Saxe JP, Mottahedeh J, Pyle AD, Wu H, and Kornblum HI. Proliferative neural stem cells have high endogenous ROS levels that regulate selfrenewal and neurogenesis in a PI3K/Akt-dependant manner. Cell Stem Cell 8: 59-71, 2011
34. Lee S, Choi H, Kim E, Kim H, Park YH, Yu DY, Yoon SJ, Kim J, Sheen Y, Park SN, and Yoon DY. Melphalan inhibits adenoma development through modulating the expression of K-ras-specific markers in K-ras Tg mice. Int J Oncol 37: 219-228, 2010
35. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, Herdman S, Varki N, Corr M, Lee J, and Raz E. ERK activation drives intestinal tumorigenesis in Apc(min/ +) mice. Nat Med 16: 665-670, 2010
36. Li L, Shoji W, Oshima H, Obinata M, Fukumoto M, and Kanno N. Crucial role of peroxiredoxin III in placental antioxidant defense of mice. FEBS Lett 582: 2431-2434, 2008
37. Liu JJ, Chao JR, Jiang MC, Ng SY, Yen JJ, and Yang-Yen HF. Ras transformation results in an elevated level of cyclin D1 and acceleration of G1 progression in NIH 3T3 cells. Mol Cell Biol 15: 3654-3663, 1995
38. Martindale JL and Holbrook NJ. Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 192: 1-15, 2002
39. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, and Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6: 1353-1362, 1991
40. Neumann CA and Fang Q. Are peroxiredoxins tumor suppressors? Curr Opin Pharmacol 7: 375-380, 2007
41. Neumann CA, Krause DS, Carman CV, Das S, Dubey DP, Abraham JL, Bronson RT, Fujiwara Y, Orkin SH, and Van Etten RA. Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature 424: 561-565, 2003
42. Palande K, Roovers O, Gits J, Verwijmeren C, Iuchi Y, Fujii J, Neel BG, Karisch R, Tavernier J, and Touw IP. Peroxiredoxin-controlled G-CSF signalling at the endoplasmic reticulum-early endosome interface. J Cell Sci 124: 3695-3705, 2011
43. Papaiahgari S, Zhang Q, Kleeberger SR, Cho HY, and Reddy SP. Hyperoxia stimulates an Nrf2-ARE transcriptional response via ROS-EGFR-PI3K-Akt/ERK MAP kinase signaling in pulmonary epithelial cells. Antioxid Redox Signal 8: 43-52, 2006
44. Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, Shin SS, Choi YH, Park KJ, Park RW, and Hwang SC. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 11: 269-275, 2006
45. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, and Park YM. Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res 67: 9294-9303, 2007
46. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, and Ewen ME. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature 386: 177-181, 1997
47. Rosseland CM, Wierod L, Flinder LI, Oksvold MP, Skarpen E, and Huitfeldt HS. Distinct functions of H-Ras and K-Ras in proliferation and survival of primary hepatocytes due to selective activation of ERK and PI3K. J Cell Physiol 215: 818-826, 2008
48. Schumacker PT. Reactive oxygen species in cancer cells: Live by the sword, die by the sword. Cancer Cell 10: 175-176, 2006
49. Shi X, Zhang Y, Zheng J, and Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 16: 1215-1228, 2012
50. Shinohara M, Shang WH, Kubodera M, Harada S, Mitsushita J, Kato M, Miyazaki H, Sumimoto H, and Kamata T. Nox1 redox signaling mediates oncogenic Ras-induced disruption of stress fibers and focal adhesions by downregulating Rho. J Biol Chem 282: 17640-17648, 2007
51. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565, 1990
52. Stresing V, Baltziskueta E, Rubio N, Blanco J, ArribaM, Valls J, Janier M, Clezardin P, Sanz-Pamplona R, Nieva C, Marro M, Dmitri P, and Sierra A. Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. Oncogene 32: 724-735, 2013
53. Sun HN, Kim SU, Huang SM, Kim JM, Park YH, Kim SH, Yang HY, Chung KJ, Lee TH, Choi HS, Min JS, Park MK, Kim SK, Lee SR, Chang KT, Lee SH, Yu DY, and Lee DS. Microglial peroxiredoxin V acts as an inducible anti-inflammatory antioxidant through cooperation with redox signaling cascades. J Neurochem 114: 39-50, 2010
54. Vachtenheim J. Occurrence of ras mutations in human lung cancer. Minireview. Neoplasma 44: 145-149, 1997
55. Vaque JP, Navascues J, Shiio Y, Laiho M, Ajenjo N, Mauleon I, Matallanas D, Crespo P, and Leon J. Myc antagonizes Rasmediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J Biol Chem 280: 1112-1122, 2005
56. Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, and Nemenoff RA. Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9. Mol Biol Cell 20: 791-800, 2009
57. Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger GR, and Chandel NS. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A 107: 8788-8793, 2010
58. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, and Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 67: 10823-10830, 2007
59. Zhang B, Su Y, Ai G, Wang Y, Wang T, and Wang F. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res (Tokyo) 46: 305-312, 2005
60. Zhang B, Wang Y, and Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286: 154-160, 2009